Osteocalcin and osteonectin immunoreactivity in the diagnosis of osteosarcoma

Julie C. Fanburg, Andrew Rosenberg, Donald L. Weaver, Kevin O. Leslie, Kenneth G. Mann, Douglas J. Taatjes, Russell P. Tracy

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Osteosarcomas (OSAs) can be difficult to distinguish histologically from tumors with significantly different biologic potentials and treatment protocols. The correct diagnosis of OSA relies on identification of malignant osteoblasts that are capable of producing neoplastic bone. To determine the use of immunohistochemistry for the diagnosis of OSA, 106 tumors from the Massachusetts General Hospital and the University of Vermont were immunostained with monoclonal antiosteocalcin (OC) and antiosteonectin (ON) antibodies. They included 42 OSAs, 25 non-bone-forming sarcomas, 24 other malignant tumors including lymphomas, carcinomas, and melanomas, and 15 benign bone tumors. Cytoplasmic staining with OC showed 70% sensitivity and 100% specificity, while staining with ON showed 90% sensitivity and 54% specificity for bone-forming tumors, consistently staining cell types other than osteoblasts. Of the OSAs, 83% demonstrated matrix staining with one or both antibodies, whereas dense collagen was negative for both antibodies in all tumors. We conclude that tumor cell cytoplasmic staining with monoclonal OC may be helpful in distinguishing OSAs from other malignancies, and staining of extracellular matrix for OC and ON antibodies concurrently may help distinguish bone matrix from dense collagen.

Original languageEnglish
Pages (from-to)464-473
Number of pages10
JournalAmerican Journal of Clinical Pathology
Volume108
Issue number4
StatePublished - Oct 8 1997
Externally publishedYes

Fingerprint

Osteonectin
Osteocalcin
Osteosarcoma
Staining and Labeling
Neoplasms
Antibodies
Osteoblasts
Bone and Bones
Collagen
Sensitivity and Specificity
Bone Matrix
Clinical Protocols
General Hospitals
Sarcoma
Extracellular Matrix
Melanoma
Lymphoma
Immunohistochemistry
Carcinoma

Keywords

  • Immunohistochemistry
  • Monoclonal antibodies
  • Osteocalcin bone G1a protein
  • Osteonectin
  • Osteosarcoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Fanburg, J. C., Rosenberg, A., Weaver, D. L., Leslie, K. O., Mann, K. G., Taatjes, D. J., & Tracy, R. P. (1997). Osteocalcin and osteonectin immunoreactivity in the diagnosis of osteosarcoma. American Journal of Clinical Pathology, 108(4), 464-473.

Osteocalcin and osteonectin immunoreactivity in the diagnosis of osteosarcoma. / Fanburg, Julie C.; Rosenberg, Andrew; Weaver, Donald L.; Leslie, Kevin O.; Mann, Kenneth G.; Taatjes, Douglas J.; Tracy, Russell P.

In: American Journal of Clinical Pathology, Vol. 108, No. 4, 08.10.1997, p. 464-473.

Research output: Contribution to journalArticle

Fanburg, JC, Rosenberg, A, Weaver, DL, Leslie, KO, Mann, KG, Taatjes, DJ & Tracy, RP 1997, 'Osteocalcin and osteonectin immunoreactivity in the diagnosis of osteosarcoma', American Journal of Clinical Pathology, vol. 108, no. 4, pp. 464-473.
Fanburg JC, Rosenberg A, Weaver DL, Leslie KO, Mann KG, Taatjes DJ et al. Osteocalcin and osteonectin immunoreactivity in the diagnosis of osteosarcoma. American Journal of Clinical Pathology. 1997 Oct 8;108(4):464-473.
Fanburg, Julie C. ; Rosenberg, Andrew ; Weaver, Donald L. ; Leslie, Kevin O. ; Mann, Kenneth G. ; Taatjes, Douglas J. ; Tracy, Russell P. / Osteocalcin and osteonectin immunoreactivity in the diagnosis of osteosarcoma. In: American Journal of Clinical Pathology. 1997 ; Vol. 108, No. 4. pp. 464-473.
@article{56e42a1cb34049adb587c88498acc0b4,
title = "Osteocalcin and osteonectin immunoreactivity in the diagnosis of osteosarcoma",
abstract = "Osteosarcomas (OSAs) can be difficult to distinguish histologically from tumors with significantly different biologic potentials and treatment protocols. The correct diagnosis of OSA relies on identification of malignant osteoblasts that are capable of producing neoplastic bone. To determine the use of immunohistochemistry for the diagnosis of OSA, 106 tumors from the Massachusetts General Hospital and the University of Vermont were immunostained with monoclonal antiosteocalcin (OC) and antiosteonectin (ON) antibodies. They included 42 OSAs, 25 non-bone-forming sarcomas, 24 other malignant tumors including lymphomas, carcinomas, and melanomas, and 15 benign bone tumors. Cytoplasmic staining with OC showed 70{\%} sensitivity and 100{\%} specificity, while staining with ON showed 90{\%} sensitivity and 54{\%} specificity for bone-forming tumors, consistently staining cell types other than osteoblasts. Of the OSAs, 83{\%} demonstrated matrix staining with one or both antibodies, whereas dense collagen was negative for both antibodies in all tumors. We conclude that tumor cell cytoplasmic staining with monoclonal OC may be helpful in distinguishing OSAs from other malignancies, and staining of extracellular matrix for OC and ON antibodies concurrently may help distinguish bone matrix from dense collagen.",
keywords = "Immunohistochemistry, Monoclonal antibodies, Osteocalcin bone G1a protein, Osteonectin, Osteosarcoma",
author = "Fanburg, {Julie C.} and Andrew Rosenberg and Weaver, {Donald L.} and Leslie, {Kevin O.} and Mann, {Kenneth G.} and Taatjes, {Douglas J.} and Tracy, {Russell P.}",
year = "1997",
month = "10",
day = "8",
language = "English",
volume = "108",
pages = "464--473",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "4",

}

TY - JOUR

T1 - Osteocalcin and osteonectin immunoreactivity in the diagnosis of osteosarcoma

AU - Fanburg, Julie C.

AU - Rosenberg, Andrew

AU - Weaver, Donald L.

AU - Leslie, Kevin O.

AU - Mann, Kenneth G.

AU - Taatjes, Douglas J.

AU - Tracy, Russell P.

PY - 1997/10/8

Y1 - 1997/10/8

N2 - Osteosarcomas (OSAs) can be difficult to distinguish histologically from tumors with significantly different biologic potentials and treatment protocols. The correct diagnosis of OSA relies on identification of malignant osteoblasts that are capable of producing neoplastic bone. To determine the use of immunohistochemistry for the diagnosis of OSA, 106 tumors from the Massachusetts General Hospital and the University of Vermont were immunostained with monoclonal antiosteocalcin (OC) and antiosteonectin (ON) antibodies. They included 42 OSAs, 25 non-bone-forming sarcomas, 24 other malignant tumors including lymphomas, carcinomas, and melanomas, and 15 benign bone tumors. Cytoplasmic staining with OC showed 70% sensitivity and 100% specificity, while staining with ON showed 90% sensitivity and 54% specificity for bone-forming tumors, consistently staining cell types other than osteoblasts. Of the OSAs, 83% demonstrated matrix staining with one or both antibodies, whereas dense collagen was negative for both antibodies in all tumors. We conclude that tumor cell cytoplasmic staining with monoclonal OC may be helpful in distinguishing OSAs from other malignancies, and staining of extracellular matrix for OC and ON antibodies concurrently may help distinguish bone matrix from dense collagen.

AB - Osteosarcomas (OSAs) can be difficult to distinguish histologically from tumors with significantly different biologic potentials and treatment protocols. The correct diagnosis of OSA relies on identification of malignant osteoblasts that are capable of producing neoplastic bone. To determine the use of immunohistochemistry for the diagnosis of OSA, 106 tumors from the Massachusetts General Hospital and the University of Vermont were immunostained with monoclonal antiosteocalcin (OC) and antiosteonectin (ON) antibodies. They included 42 OSAs, 25 non-bone-forming sarcomas, 24 other malignant tumors including lymphomas, carcinomas, and melanomas, and 15 benign bone tumors. Cytoplasmic staining with OC showed 70% sensitivity and 100% specificity, while staining with ON showed 90% sensitivity and 54% specificity for bone-forming tumors, consistently staining cell types other than osteoblasts. Of the OSAs, 83% demonstrated matrix staining with one or both antibodies, whereas dense collagen was negative for both antibodies in all tumors. We conclude that tumor cell cytoplasmic staining with monoclonal OC may be helpful in distinguishing OSAs from other malignancies, and staining of extracellular matrix for OC and ON antibodies concurrently may help distinguish bone matrix from dense collagen.

KW - Immunohistochemistry

KW - Monoclonal antibodies

KW - Osteocalcin bone G1a protein

KW - Osteonectin

KW - Osteosarcoma

UR - http://www.scopus.com/inward/record.url?scp=0030821118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030821118&partnerID=8YFLogxK

M3 - Article

C2 - 9322601

AN - SCOPUS:0030821118

VL - 108

SP - 464

EP - 473

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 4

ER -